Macular degeneration diseases
Conditions
Interventions
One cohort:stem cell transplantation
Sponsors
Southwest Hospital, Shapingba District, Chongqing, China
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aging from 18 to 65 years who have signed informed consent for the clinical trial; 2. Patients who have at least one visually impaired eye caused by macular degeneration diseases; 3. Juvenile patients with macular degeneration diseases and patients with age-related macular degeneration diseases who can not be effectively treated with conventional therapies; 4. Eyes under following conditions: 1) Using the early treatment diabetic retinopathy (ETDRs) eye chart in 4 meters distance detection, best corrected visual acuity scores between 19 and 73 letter, including 19 and 73 (or the equivalent of about Snellen eyesight from 20/400 to 20/40); 2) Visual loss is caused by macular degeneration diseases.
Exclusion criteria
Exclusion criteria: 1. Patient with concomitant eye conditions/diseases incuding: (1) Eyes with concomitant diseases which will interfere the visual improvement of the study; (2) Either eye has active intraocular inflammation regardless of the grade of severity; (3) Either eye has active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, ophthalmia); (4) Either eye has a history of uveitis; (5) Any significant ocular disease that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome, including severe cataract, glaucoma, retinal blood vessels occlusion, retinal detachment, macular hole, vitreous-macula traction; (6) Either eye has iris neovascularization (7) Patients who have only one functioning eye, or the best corrected vision of untreated eye scores less than 24 letters in ETDRS chart(corresponding to 20/320 in Snellen chart). 2. Eyes with history of intraocular surgeries; 3. Patients with systemic conditions including (1) stroke, coronary heart disease, angina pectoris, renal insufficiency needing dialysis, and other systemic diseases that are not suitable to the clinical trial; (2) patients who are allergic to sodium fluorescein; (3) uncontrolled hypertension (systolic pressure>140mmHg,or diastolic pressure>90mmHg); (4) coaggulative function disorder or patients who are using anticoagulant drugs; (5) patients who are using or are going to systemically use drugs that are toxic to lens, retina, or optic nerve like hydroxychloroquine, phenothiazine, ethambutol, tamoxifen, etc.; (6) patients who attended other clinical trials of any medicine within 1 month (or within 5 half-life periods). 4. others (1) patients who have maternity plan in 6 months; (2) women patients who are in pregnancy or lactation period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early treatment of diabetic retinopathy eye chart (ETDRs);Fluorescein angiography;Static perimetry;Optical coherent tomography (OCT);Flash electroretinogram (FERG);Flash Visual Evoked Potentials;mutifocal electroretinogram (MFERG); | — |
Countries
China
Contacts
Public ContactYin Zhengqin
Outcome results
None listed